Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Metadata
Title
The Pathophysiology of Acute Graft-versus-Host Disease
Authors
James L. M. Ferrara
Kenneth R. Cooke
Takanori Teshima
Publication date
01-10-2003
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2003
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF02983793

Other articles of this Issue 3/2003

International Journal of Hematology 3/2003 Go to the issue

Letter to the Editor

Hyperthermia-Induced Pseudopodia (Thermopodia) Are Observed in Neutrophils from Febrile Patients

Letter to the Editor

Intensified Conditioning Regimen Has Only Limited Value for Patients with Progressive Multiple Myeloma

OriginalPaper

N-(4-Hydroxyphenyl)retinamide (4-HPR) Induces Leukemia Cell Death via Generation of Reactive Oxygen Species

Case Report

Membranous Nephropathy Associated with Donor Lymphocyte Infusion following Allogeneic Bone Marrow Transplantation

Case Report

Induction of Umbilical Cord Blood Mesenchymal Stem Cells into Neuron-Like Cells In Vitro

OriginalPaper

Targeting Alloreactive Donor T-Cells to Hematopoietic System-Restricted Minor Histocompatibility Antigens to Dissect Graft-versus-Leukemia Effects from Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits